Peroxisome proliferator-activated receptors in cutaneous biology

British Journal of Dermatology

Volumn 149, Issue 2, 2003, Pages 229-236

  Kuenzli, Stéphane ^a   Saurat, J H ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Differentiation; Peroxisome proliferator activated receptors; Proliferation; Psoriasis; Wound healing

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEINASE INHIBITOR; THIOACETIC ACID; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACNE; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; EPIDERMIS CELL; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KERATINOCYTE; LIPODYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PSORIASIS; REVIEW; SKIN DISEASE; SKIN INFILTRATE; SKIN INFLAMMATION; SKIN PERMEABILITY; UPREGULATION; WOUND HEALING;

ANIMALS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MICE; PSORIASIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SKIN; SKIN PHYSIOLOGY; TRANSCRIPTION FACTORS; WOUND HEALING;

EID: 0041411241     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05532.x     Document Type: Review

References (58)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-50.
2. Kliewer SA, Lehmann JM, Willson TM. Orphan nuclear receptors: shifting endocrinology into reverse. Science 1999; 284: 757-60.
3. Dreyer C, Krey G, Keller H et al. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992; 68: 879-87.
4. Kliewer SA, Forman BM, Blumberg B et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994; 91: 7355-9.
5. Zhu Y, Alvares K, Huang Q et al. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem 1993; 268: 26817-20.
6. Gonzalez FJ. The role of peroxisome proliferator activated receptor alpha in peroxisome proliferation, physiological homeostasis, and chemical carcinogenesis. Adv Exp Med Biol 1997; 422: 109-25.
7. Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 2002; 59: 790-8.
8. Jump DB, Clarke SD. Regulation of gene expression by dietary fat. Annu Rev Nutr 1999; 19: 63-90.
9. Devchand PR, Keller H, Peters JM et al. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384: 39-43.
10. Staels B, Koenig W, Habib A et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998; 393: 790-3.
11. Kippenberger S, Loitsch SM, Grundmann-Kollmann M et al. Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation. J Invest Dermatol 2001; 117: 1430-6.
12. Sheu MY, Fowler AJ, Kao J et al. Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol 2002; 118: 94-101.
13. Chinetti G, Lestavel S, Bocher V et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53-8.
14. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-4.
15. Houseknecht KL, Cole BM, Steele PJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 2002; 22: 1-23.
16. Matsuura H, Adachi H, Smart RC et al. Correlation between expression of peroxisome proliferator-activated receptor beta and squamous differentiation in epidermal and tracheobronchial epithelial cells. Mol Cell Endocrinol 1999; 147: 85-92.
17. Law RE, Meehan WP, Xi XP et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98: 1897-905.
18. Morikang E, Benson SC, Kurtz TW, Pershadsingh HA. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens 1997; 10: 440-6.
19. Sarraf P, Mueller E, Jones D et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046-52.
20. Kubota T, Koshizuka K, Williamson EA et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-52.
21. Mueller E, Sarraf P, Tontonoz P et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465-70.
22. Mossner R, Schulz U, Kruger U et al. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 2002; 119: 576-82.
23. Peters JM, Lee SS, Li W et al, Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta (delta). Mol Cell Biol 2000; 20: 5119-28.
24. Lim H, Gupta RA, Ma WG et al. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev 1999; 13: 1561-74.
25. Leibowitz MD, Fievet C, Hennuyer N et al. Activation of PPAR-delta alters lipid metabolism in db/db mice. FEBS Lett 2000; 473: 333-6.
26. Westergaard M, Henningsen J, Svendsen ML et al. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol 2001; 116: 702-12.
27. Oliver WR Jr, Shenk JL, Snaith MR et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001; 98: 5306-11.
28. Hanley K, Komuves LG, Bass NM et al. Fetal epidermal differentiation and barrier development in vivo is accelerated by nuclear hormone receptor activators. J Invest Dermatol 1999; 113: 788-95.
29. Braissant O, Foufelle F, Scotto C et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha-beta, and -gamma in the adult rat. Endocrinol 1996; 137: 354-66.
30. Braissant O, Wahli W. Differential expression of peroxisome proliferator-activated receptor-alpha-beta, and -gamma during rat embryonic development. Endocrinology 1998; 139: 2748-54.
31. Michalik L, Desvergne B, Tan NS et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta mutant mice. J Cell Biol 2001; 154: 799-814.
32. Rivier M, Safonova I, Lebrun P et al. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol 1998; 111: 1116-21.
33. Ellis CN, Varani J, Fisher GJ et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000; 136: 609-16.
34. Lee SS, Pineau T, Drago J et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Bid 1995; 15: 3012-22.
35. Barak Y, Nelson MC, Ong ES et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4: 585-95.
36. Rosen ED, Sarraf P, Troy AE et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999; 4: 611-17.
37. Hanley K, Jiang Y, Crumrine D et al. Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier. J Clin Invest 1997; 100: 705-12.
38. Komuves LG, Hanley K, Jiang Y et al. Ligands and activators of nuclear hormone receptors regulate epidermal differentiation during fetal rat skin development. J Invest Dermatol 1998; 111: 429-33.
39. Komuves LG, Hanley K, Man MQ et al. Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARalpha activators restores tissue homeostasis. J Invest Dermatol 2000; 115: 361-7.
40. Komuves LG, Hanley K, Lefebvre AM et al. Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol 2000; 115: 353-60.
41. Hanley K, Jiang Y, He SS et al. Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARalpha. J Invest Dermatol 1998; 110: 368-75.
42. Rivier M, Castiel I, Safonova I et al. Peroxisome proliferator-activated receptor-alpha enhances lipid metabolism in a skin equivalent model. J Invest Dermatol 2000; 114: 681-7.
43. Tan NS, Michalik L, Noy N et al. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 2001; 15: 3263-77.
44. Wahli W. Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Med Wkly 2002; 132: 83-91.
45. Grose R, Werner S. An aPPARently protective mechanism for keratinocytes in wounded skin. Trends Mol Med 2002; 8: 149-51.
46. Rosenfield RL, Deplewski D, Kentsis A, Ciletti N. Mechanisms of androgen induction of sebocyte differentiation. Dermatol 1998; 196: 43-6.
47. Rosenfield RL, Kentsis A, Deplewski D, Ciletti N. Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors. J Invest Dermatol 1999; 112: 226-32.
48. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev 2000; 21: 363-92.
49. Carr A, Samaras K, Chisholm DJ. Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-3.
50. Bastard JP, Caron M, Vidal H et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: 1026-31.
51. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. J Endocrinol 2000; 164: R7-10.
52. Lebwohl M, Ali S. Treatment of psoriasis. Part 1, Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487-98: quiz 499-502.
53. Kuenzli S, Saurat JH. Retinoids for the treatment of psoriasis: outlook for the future. Curr Opin Invest Drugs 2001; 2: 625-30.
54. Pershadsingh HA, Sproul JA, Benjamin E et al. Treatment of psoriasis with troglitazone therapy. Arch Dermatol 1998; 134: 1304-5.
55. Kuenzli S, Perriard J, Piguet V et al. Topical clofibrate for psoriasis. International Psoriasis Symposium and European Congress on Psoriasis, 2nd Joint Meeting, San Francisco 19-24 June 2001.
56. Kuenzli S, Saurat JH. Topical PPARβ/δ and PPARγ agonists on plaque psoriasis: a pilot study. Dermatology 2003; 206: 252-6.
57. Kliewer SA, Umesono K, Noonan DJ et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771-4.
58. Mukherjee R, Strasser J, Jow L et al. RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arterioscler Thromb Vasc Biol 1998; 18: 272-6.